News & Events about Arbutus Biopharma Corporation.
Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (Arbutus or the Company), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to ...
TipRanks Financial Blog
1 year ago
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arbutus Biopharma (ABUS Research Report) and Evoge... Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arbutus Biopharma (ABUS Research Report) and ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS PR Newswire NEW YORK, May 2, 2023 NEW YORK, May 2, 2023...
Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post-AB-729 treatment AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in preclinical models WARMINSTER, Pa., April...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS PR Newswire NEW YORK, April 26, 2023 NEW YORK, April 26...